# Endogena Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/endogena-therapeutics

- Industry: Biotechnology
- Headquarters: San Francisco, US
- Website: www.endogena.com
- Total disclosed funding: $15M
- Latest round: Series A (Dec 13, 2021)
- Investors on record: 2

## About

Endogena Therapeutics focuses on developing innovative regenerative medicines that target degenerative diseases of vision and lung function, utilizing advanced small molecule therapies for potential treatment options.Founded in 2016 in San Francisco, US, Endogena Therapeutics, Inc. specializes in regenerative medicine solutions. The company has secured funding through its Series A round, raising USD 7.34 mn in December 2021, led by Rejuveron Life Sciences, with participation from DEFTA Partners. The total amount raised by the company stands at USD 7.34 mn, with a current valuation of USD 91.48 mn. Matthias Steger serves as the CEO, steering the company through its innovative mission in the biotechnology space.Endogena Therapeutics specializes in the discovery and development of endogenous regenerative medicines aimed at treating degenerative diseases, particularly those affecting vision and lung function. The company’s primary offerings include innovative small molecule therapies designed to selectively regulate adult stem and progenitor cells for tissue repair. Their lead product, EA-2353, targets retinitis pigmentosa, a genetic disorder that leads to progressive vision loss, and is currently in Phase 1/2a clinical trials. The company aims to address significant unmet medical needs in markets across North America and Europe, specifically targeting healthcare providers and institutions involved in ophthalmology and pulmonary care. Endogena's products are underpinned by recent advancements in stem cell biology and functional screening technologies, demonstrating their commitment to leveraging cutting-edge science to improve patient outcomes.Endogena Therapeutics generates revenue primarily through partnerships with healthcare institutions and by progressing its clinical trial programs for novel therapies. The company may engage in collaborative agreements with pharmaceutical firms and research organizations, facilitating the development and commercialization of its products. While specific pricing structures for their therapies are not disclosed, typical transactions may involve milestone payments tied to clinical trial advancements, as well as potential royalties on future sales of approved products. The company's flagship therapy, EA-2353, is expected to attract interest from healthcare providers seeking innovative treatments for patients with retinitis pigmentosa, contributing to their revenue model. Endogena's focus on high unmet medical needs positions them favorably within the biotechnology landscape, aligning with the demand for effective therapeutic options in degenerative diseases.Endogena Therapeutics plans to utilize the recent USD 7.34 mn raised in Series A funding to advance its lead program, EA-2353, a treatment for retinitis pigmentosa, through first-in-human trials in the USA. Additionally, the funding will support the advancement of EA-2351, a treatment for geographic atrophy, towards an Investigational New Drug application. The company is targeting expansion into North America and Europe, with a focus on ophthalmology and pulmonary care markets.

## Funding rounds

- Series A, Dec 13, 2021, $7.3M — DEFTA Partners, Centenara Labs
- Series A, Dec 21, 2020, $8M — DEFTA Partners, Centenara Labs

## Investors

- DEFTA Partners (https://capitalatlas.ai/funds/defta-partners) — Series A
- Centenara Labs (https://capitalatlas.ai/funds/centenara-labs) — Series A